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ABSTRACT: The posttranscriptional modification of riboso-
mal RNA (rRNA) modulates ribosomal function and confers
resistance to antibiotics targeted to the ribosome. The radical
S-adenosyl-L-methionine (SAM) methyl synthases, RlmN and
Cfr, both methylate A2503 within the peptidyl transferase
center of prokaryotic ribosomes, yielding 2-methyl- and 8-
methyl-adenosine, respectively. The C2 and C8 positions of adenosine are unusual methylation substrates due to their
electrophilicity. To accomplish this reaction, RlmN and Cfr use a shared radical-mediated mechanism. In addition to the radical
SAM CX3CX2C motif, both RlmN and Cfr contain two conserved cysteine residues required for in vivo function, putatively to
form (cysteine 355 in RlmN) and resolve (cysteine 118 in RlmN) a covalent intermediate needed to achieve this challenging
transformation. Currently, there is no direct evidence for this proposed covalent intermediate. We have further investigated the
roles of these conserved cysteines in the mechanism of RlmN. Cysteine 118 mutants of RlmN are unable to resolve the covalent
intermediate, either in vivo or in vitro, enabling us to isolate and characterize this intermediate. Additionally, tandem mass
spectrometric analyses of mutant RlmN reveal a methylene-linked adenosine modification at cysteine 355. Employing deuterium-
labeled SAM and RNA substrates in vitro has allowed us to further clarify the mechanism of formation of this intermediate.
Together, these experiments provide compelling evidence for the formation of a covalent intermediate species between RlmN
and its rRNA substrate and well as the roles of the conserved cysteine residues in catalysis.
■ INTRODUCTION
The ribosome, containing both ribosomal proteins and
ribosomal RNA (rRNA), catalyzes the biosynthesis of proteins
critical to cellular function. Within the ribosome, it is the rRNA
components that play the predominant structural and func-
tional roles. Owing to its indispensible activity, the bacterial
ribosome is a frequent target of antibiotic agents.1 Unsurpris-
ingly, compounds that interact with the ribosome and interfere
with protein synthesis make close contacts with the rRNA
located in functionally important regions of the ribosome.2−5
Consequently, modifications to the rRNA in these regions can
abrogate binding of antibiotics, leading to restoration of
ribosomal activity and antibiotic resistance. One of the most
common rRNA modifications leading to antibiotic resistance is
the S-adenosyl-L-methionine (SAM)-dependent installation of a
methyl group on a specific nucleobase.6 The recently
discovered, clinically significant resistance enzyme, Cfr,
catalyzes the formation of an 8-methyladenosine residue at
position 2503 (Escherichia coli numbering) of 23S rRNA,7
which resides within the peptidyl transferase center (PTC) of
the bacterial ribosome. This modification confers resistance to
five classes of PTC-targeted antibiotics,8 including the synthetic
oxazolidinone linezolid, an agent commonly reserved as a “last
line of defense” against resistant pathogens. RlmN, a
homologue of Cfr, modifies the same adenosine base as Cfr
(A2503),9 resulting in the formation of 2-methyladenosine.10
RlmN has recently been demonstrated to methylate adenosine
residues at position 37 of several E. coli transfer RNAs,
indicating a broader substrate specificity and a larger role in
fine-tuning interactions critical to translation.11 While the
biological role of Cfr’s activity may be more striking,8 the
positioning of the constitutive RlmN modification at the
intersection of the PTC and the exit tunnel, as well as the
impact of the modified base on ribosomal interactions with the
nascent polypeptide, makes this modification no less critical to
understand.12,13
These two homologous enzymes are members of the radical
SAM superfamily and are presumed to employ a shared, radical-
based mechanism to modify the target base in rRNA.10,14,15
Both Cfr and RlmN contain the conserved CX3CX2C cysteine-
rich motif, which ligates the [4Fe-4S] iron−sulfur cluster
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employed by all members of the radical SAM superfamily.16
Members of this class of enzymes have been implicated in a
broad range of pathways and reactions,17,18 catalyzing amine
shifts,19−23 nucleotide reduction,24−26 sulfur insertions,27−32
DNA repair,33,34 methylthiolation,35−40 oxidative decarboxyla-
tion,41−43 peptide modifications,44−47 and complex rearrange-
ments48 among many others. Within this superfamily, RlmN
and Cfr are the only known examples of methyl synthases, and
both assemble a methyl group on their products from a
hydrogen atom initially present on the substrate and a
methylene fragment ultimately derived from SAM.14,15
These methyl synthases share significant homology, includ-
ing two conserved cysteine residues that are not associated with
the iron−sulfur cluster: cysteines 105 and 338 in Cfr and
cysteines 118 and 355 in RlmN. These residues are proposed to
play important roles in catalysis. Prior in vivo work indicates
that both of these cysteines are crucial to the ability of Cfr to
elicit antibiotic resistance.49 Further, primer extension assays
demonstrated that rRNA isolated from C105A mutant strains
exhibits a strong stop at A2503, consistent with a modification
other than a methyl groupwhich yields a weaker stop.49
In conjunction with the foregoing in vivo data, elegant single-
turnover experiments14 and an X-ray crystallographic structure
of RlmN50 point to a pathway initiated by the pre-methylation
of cysteine 355 (RlmN numbering), by a first molecule of SAM
bound at the [4Fe-4S] cluster, followed by the binding of a
second molecule of SAM. With the injection of an electron, the
5′-deoxyadenosyl (5′-dA) radical formed from the second
equivalent of SAM activates the thiomethyl group at cysteine
355 by abstracting a hydrogen atom. The resulting thio-
methylene radical adds into the adenine ring of A2503. Loss of
an electron from this initial adduct (species IV in Scheme 1),
possibly to the now oxidized [4Fe-4S] cluster,51 leads to the
formation of a covalent RlmN-RNA thioether species. This
adduct is subsequently resolved by the action of cysteine 118 in
conjunction with acid/base catalysis (Scheme 1).14
While this proposed mechanism is consistent with the
observed formation of the thiomethyl species on cysteine 355,
no conclusive evidence of the putative intermediate species has
been provided. To address this uncertainty, we sought to
characterize the mechanistically critical RNA-protein adduct
(VI in Scheme 1). Herein, we describe a combination of in vivo
and in vitro approaches to characterize the adduct formed
between RlmN and RNA as well as its mechanism of formation.
■ EXPERIMENTAL PROCEDURES
General. Anaerobic manipulations were carried out in a glovebox
(MBraun) under a 99.997% nitrogen atmosphere containing less than
2 ppm oxygen. All reagents were analytical grade or the highest grade
commercially available and used as supplied unless noted otherwise.
Iron quantitation,10,52 preparation of truncated rRNA substrates,10
RNA digestion,10 high-performance liquid chromatography (HPLC)
separation, and liquid chromatography-mass spectrometry (LC-MS)
analysis of nucleotides15 were performed as previously noted. The
RlmN C118S and C118G mutants were generated from the C118A
mutant plasmid under conditions analogous to those previously
employed, using the oligonucleotide primers noted in the Supporting
Information (Table S1), and the DNA sequence was confirmed (Elim
Biopharmaceuticals, Inc.).
Expression, Purification, and Reconstitution of Wild-Type
and Mutant RlmN. Wild-type (WT) RlmN and C355A RlmN were
expressed, purified, and reconstituted as described previously.10,14
C118 mutants were prepared by modified versions of those previous
protocols. Holo-C118A/G/S RlmN was overexpressed and purified by
His6 affinity chromatography with Talon resin. Anion exchange
chromatography, employing either HiTrap Q10 or MonoQ columns
(GE) was subsequently used to separate protein covalently modified
by RNA in vivo from RNA-unmodified protein. These proteins were
reconstituted and further purified by size exclusion chromatography
prior to use. Apo-C118S RlmN was overexpressed and purified as
described previously for WT apoprotein.53 This protein did not form
an RNA-RlmN adduct in vivo (see below), so the anion-exchange step
noted above was omitted, and the remainder of the protocol was
performed as described. RNA-RlmN adduct samples to be analyzed by
RNA-digest, gel-shift, or MS methods were subjected to RNase
treatment with a mixture of RNases A and T1 (Thermo) according to
the manufacturer’s protocol. The in-gel RNase digestion protocol is
similar and is described in detail in the Supporting Information.
2-Methyladenosine Production by Wild-Type, C118, and
C355 Mutant RlmN. In order to assess the ability of mutant proteins
to install methyl groups on RNA substrates, the amount of 2-
methyladenosine from hydrolysates of RNA reacted with mutant
enzymes was compared to that from WT. As previous work indicated
that flavodoxin (FldA)54 and its cognate reductase (Fpr)55 were a
suitable reducing system for RlmN and Cfr activity assays,14 these
proteins were employed in our assays. 250 μL reactions were
performed under the following conditions: 200 mM 4-(2-hydrox-
yethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 500 mM
KCl, 10 mM MgCl2, 2 mM dithiothreitol (DTT), 200 μM SAM, 20
μM RNA (rRNA truncation 2496−2582), and 25 μM RlmN WT or
mutant enzyme. The reducing system was composed of 20 μM FldA, 2
μM Fpr and 2 mM reduced nicotinamide adenine dinucleotide
phosphate (NADPH), and reactions were allowed to proceed for 1 h
at 37 °C. The RNA was recovered from the reactions, digested and
separated as previously. Fractions corresponding to the elution time of
authentic 2-methyladenosine were lyophilized and further analyzed by
LC-MS to detect the presence of a species at m/z = 282 corresponding
to intact 2-methyladenosine as previously. To determine the threshold
of detection of 2-methyladenosine from WT enzyme, the 2-
methyladenosine from WT reactions corresponding to between 25
and 500 nmol of recovered RNA were analyzed. Subsequently, samples
that would contain any 2-methyladenosine produced in reactions of
C355A, C118A, or C118S and corresponding to between 600 and
2000 nmol of RNA were analyzed in an identical fashion. If no 2-
methyladenosine can be detected in a mutant sample representing 10
Scheme 1. Proposed Mechanism of RlmN-Mediated
Methylation of RNA
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times the RNA of the threshold amount of WT RNA, the mutant was
presumed to have less than 10% of WT activity, allowing for threshold
activities of mutants to be established.
Generation of Endogenous RlmN-FLAG. A C-terminal
DYKDDDDK octapeptide (FLAG) sequence was fused to the
genomic version of rlmN on the chromosome of E. coli using the
techniques and constructs first described by Datsenko and Wanner.56
The C-terminal FLAG sequence was incorporated into the primer pair
(Table S1) used to amplify kan from pKD4 via polymerase chain
reaction (PCR).56 This PCR product was transformed into E. coli
strain BW25113 carrying the λ-red system on pKD46,56 and successful
incorporation onto the chromosome was selected through kanamycin
resistance. The kanamycin resistance cassette was removed using the
FLP expression plasmid pCP20, and the tagged locus was verified by
sequencing. These strains were used in subsequent immunoprecipi-
tation experiments.
Immunoprecipitation of Endogenous RlmN-FLAG. An over-
night culture of E. coli BW25113 in which a C-terminal FLAG
sequence was fused to the genomic copy of rlmN was diluted 1:100
into fresh Luria−Bertani (LB) medium, grown at 37 °C with agitation
at 200 rpm, and aliquots were removed at 30-min intervals. Cell pellets
were frozen at −80 °C and all processed after collection of the final
time point. Cells were lysed using BugBuster protein extraction
reagent according to the manufacturer’s instructions, and protein
concentrations were determined by the method of Bradford.57 Ten μg
of total protein from each time-point was run on a polyacrylamide gel
and the protein was subsequently electroblotted to a PVDF
membrane. Proteins bearing a FLAG-tag were detected with an anti-
FLAG horseradish peroxidase conjugated antibody and visualized by
chemiluminescence.
A 4-L portion of LB medium was inoculated 1:100 from an
overnight culture of E. coli expressing the FLAG-tagged endogenous
RlmN. The cells were harvested after 90 min. The resulting cell pellet
was resuspended in 5 mL of Tris-buffered saline containing Tween-20,
containing 1 mM ethylenediaminetetraacetic acid and 100 μM
phenylmethanesulfonyl fluoride, and lysed by sonication. The resulting
lysate was treated with anti-FLAG M2 affinity gel as per the
manufacturer’s instructions to isolate FLAG fusion proteins. The
resulting FLAG fusions were separated by sodium dodecyl sulfate−
polyacrylamide gel electrophoresis (SDS-PAGE), and the band
exhibiting the expected molecular weight (MW) of RlmN-FLAG
(∼45 kDa) was excised from the gel. The protein was subjected to in-
gel trypsin digestion and the tryptic peptides were characterized by
LC-MS/MS as described in the Supporting Information.
Generation and PAGE Analysis of in Vitro Generated RNA-
RlmN C118 Mutant Adduct. Reactions to form an RNA-protein
adduct from T7-transcribed RNA and purified C118 mutant enzyme
were performed with two types of RlmN samples. The first were Fe−S
cluster-containing C118 mutant proteins purified away from the in vivo
RNA-RlmN adduct, exhibiting chromatographic behavior similar to
WT and either methylated or unmodified at C355. The second were
apo (Fe−S cluster-free) versions of C118 mutant RlmN expressed in
minimal media under iron-deficient conditions in the presence of a
strong chelating agent. Apo-RlmN had previously been shown to lack
methylation at C355,53 and we further examined whether C118 RlmN
mutants expressed under these conditions formed adducts in vivo or
could form adducts in vitro. As such, they were purified and
reconstituted as previously indicated. In order to assess the ability of
these unmodified mutant proteins to form RNA-RlmN adducts in
vitro, small scale (50−100 μL) reactions were performed under the
following conditions: 200 mM HEPES pH 7.5, 500 mM KCl, 10 mM
MgCl2, 1 mM DTT, 100 μM SAM (200 μM with apo, reconstituted
samples to compensate for the lack of any C355 methylation), 25 μM
RlmN mutant enzyme, and 20 μM RNA encompassing residues
2496−2582 of 23S rRNA. The reducing system was composed of 20
μM FldA, 2 μM ferrodoxin:NADPH oxidoreductase and 2 mM
NADPH. All assays were initiated by the addition of RlmN. Aliquots of
the reaction mixtures were separated by PAGE in gels containing 5%
polyacrylamide, 7 M urea, and 0.1% SDS; RNA species were visualized
by ethidium bromide staining and imaged using a Typhoon imaging
system.
Mass Spectrometry. Tryptic digests were analyzed on an LTQ-
Orbitrap XL or VELOS hybrid tandem mass spectrometer (Thermo
Scientific) coupled with a nanoACQUITY HPLC system (Waters) in
LC-MS/MS mode. Details of the HPLC separation are provided in the
Supporting Information. Mass measurements (MS survey) were
performed in the Orbitrap with high resolution and mass accuracy;
collision-induced dissociation (CID) experiments were performed in
the linear ion trap on computer-selected, multiply charged precursor
ions properly adjusting the CID conditions to the m/z and z values of
the precursor ions.
Data Processing. Peak lists were generated from the raw data files
using an in-house peak-picking software, PAVA. With the peak list, a
strict database search was performed using the search engine, Protein
Prospector (http://prospector.ucsf.edu), against the SwissProt data-
base, with no species specificity, permitting only tryptic cleavages (1
missed cleavage). Cysteine carbamidomethylation was a fixed
modification; methionine oxidation, N-terminal glutamine cyclization,
and protein acetylation as variable modifications were considered.
Mass accuracy was 20 ppm for the precursor ions, and 0.8 Da for the
fragments. Once it was established that RlmN was indeed present and
at a reasonable purity, a subsequent search was performed targeting
unspecified modifications occurring on the protein in general or
specifically on cysteine residues.58 Finally, the CID data supporting the
assignments were carefully inspected, and the mass accuracy of the
precursor ions was manually calculated. This latter step was necessary
because the software only indicates potential mass modification at
certain residues, without providing an elemental composition.
■ RESULTS
Mutant Activity Compared to Wild-Type. Prior in vivo
experiments with Cfr and its cysteine mutants have implicated
cysteine 105 and cysteine 338 as necessary to catalyze the 8-
methyl modification of A2503.49 Therefore we anticipated that
corresponding mutations to RlmN cysteines 118 and 355,
would result in enzymes with virtually no ability to form 2-
methyladenosine on RNA substrates. Using known quantities
of RNA recovered from in vitro WT reactions as a frame of
reference, we were able to establish a detection limit for the 2-
methyladenosine product to which the products of mutant
reactions could be compared. Whereas the 2-methyladenosine
from 25 nmol of RNA from a WT reaction was still detectable
(Figure S1), no signal was evident from between 600 and 2000
nmol of RNA from mutant reactions under identical conditions.
From these results, it was determined that C355A, C118A and
C118S exhibit ≤1.3, 3.1, and 4.2% of WT activity, respectively.
These low activities agree well with the putatively indispensible
roles of the conserved cysteine residues implicated in prior in
vivo experiments, as well as the proposed chemical mechanism
(Scheme 1).
Methylation of Endogenous RlmN. Previously, overex-
pressed RlmN has been shown to be methylated at cysteine 355
by both X-ray crystallographic analysis50 and protease digestion
followed by LC-MS/MS.14 To evaluate the methylation state of
the protein during active rRNA modification and ribosome
assembly, the genomic copy of rlmN was altered to encode a C-
terminal FLAG sequence to ensure that all experiments were
performed under conditions where RlmN was expressed at its
normal cellular level. Time-dependent expression of RlmN-
FLAG was evaluated by Western blotting for the RlmN-FLAG
in lysates at various time points (Figure S2). RlmN-FLAG is
maximally expressed ∼90 min after dilution of a saturated
culture 1:100 into fresh LB medium, corresponding to an
OD600 of ∼0.25. This timing is consistent with the growth rate-
dependent control observed for ribosome biosynthesis,59
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suggesting that RlmN produced under these conditions is the
catalytically relevant resting state of the enzyme. RlmN-FLAG
was immunoprecipitated from the 90-min time point and the
isolated protein was characterized by tryptic digestion, LC-MS/
MS similar to prior experiments.14 This analysis revealed the
peptide encompassing residues 348−365 yields an m/z(2+) =
909.4149 species consistent with methylated peptide (calcu-
lated value = 909.4203, mass difference of 6 ppm).
Fragmentation of this precursor ion yielded b/y series ions
that confirmed the site of the methyl modification as cysteine
355,60 indicating modification of the enzyme under physio-
logical conditions (Figure S3).
Characterization of RNA-RlmN C118 Mutant Adduct
Formation in Vivo. Prior in vivo work with C105A Cfr
demonstrated a strong stop at A2503 of the isolated rRNA in
primer extension assays, indicating a significant perturbation of
the rRNA at this position, although the precise nature of this
change was not assessed.49 These observations are consistent
with the attachment of a large substituent to A2503 and
possibly the formation of a covalent adduct between Cfr and
rRNA at A2503 in vivo. C118A RlmN was also shown to exhibit
a shift in its λmax from 278 to 265 nm in addition to the release
of modified RNA nucleotides upon RNase and phosphatase
treatment; however, no direct evidence of covalent attachment
or the putative points of attachment between C118A RlmN and
RNA was provided.14 To further investigate the possibility that
a covalent adduct between RNA and RlmN cysteine 118
mutant enzymes forms in vivo, the C118A, C118G, and C118S
mutants of RlmN were overexpressed and purified by Talon
chromatography. The various mutants were examined to
determine if the nature of the residue at position 118 might
influence the relative amounts of RNA-adducted and
unmodified protein. When the isolated His-tagged proteins
were analyzed by SDS-PAGE, the samples exhibited two
distinct bands, one at the native MW of RlmN, 43 kDa, and the
second at ∼65 kDa (Figure 1a,b). From this analysis, it
appeared that the C118S RlmN formed the greatest proportion
of adduct in vivo, so it was employed in subsequent in vitro
experiments (see below). In the case of C118A RlmN, when
this heterogeneous material was purified by anion exchange
chromatography, the two species were resolved, with the lower
MW species eluting at a much lower salt concentration than the
higher MW species (Figure S4). This observation is indicative
of the higher MW species being much more anionic in
character at pH 7.5−8. This higher MW species also exhibits a
much greater absorbance at 260 nm than the lower MW
species. Together, these results are consistent with the addition
of the polyanionic phosphate backbone of an RNA molecule to
the protein. Further, when the putative RNA-RlmN adduct
purified by anion exchange was treated with a mixture of
RNases A and T1, the resulting protein exhibited native-like
MW (Figure 1c). This native-like, RNase-treated material was
analyzed by tryptic digestion, LC-MS/MS, revealing the
peptide containing cysteine 355 is modified by a 147 Da
species (Figure 2). The modified peptide was chromato-
graphically resolved from the unmodified or S-methylated
peptide, and the precursor ion bearing the +147 Da
modification was subjected to CID analysis. In this instance,
the fragment ions were measured in the Orbitrap with high
resolution and mass accuracy, and the main sequence ions
unambiguously indicate that the modification resides on C355
(Figure 2). The observed mass of 147 Da is consistent with a
methylene-linked adenine adduct analogous to the covalent
intermediate species in the proposed mechanism (VI in Scheme
1). Though these samples were not specifically treated to cleave
the glycosidic bonds between the RNA nucleobases and ribose,
it appears that the linkage is not stable under the experimental
conditions. Interestingly, when C118S RlmN was prepared as
the apoprotein (lacking the Fe−S cluster), the material
exhibited only one band at the native MW of 43 kDa (Figure
1d). This observation is consistent with the previously noted
requirement of an intact Fe−S cluster for S-methylation,53 as
well as the requirement of the cluster for subsequent radical
SAM chemistry and adduct formation.
RNA-RlmN C118 Mutant Adduct Formation in Vitro.
To investigate whether a covalent adduct between RlmN
cysteine 118 mutants and RNA also forms in vitro, the
recombinant mutant proteins C118A and C118S were
incubated with an RNA fragment encompassing residues
2496−2582 of 23S rRNA and the FldA reducing system. In
light of the previously observed protein gel-shift of the in vivo
RNA-modified material (Figure 1a−c), a gel-shift assay
monitoring RNA was employed to monitor covalent
modification of the RNA fragments in vitro. When RNA from
these reactions is separated by PAGE and visualized with
ethidium bromide, complete reaction mixtures containing
C118A or C118S demonstrate two distinct bands (Figure 3,
lanes 4 and 5, respectively). The first species is unreacted RNA
(87 nt, ∼28 kDa); the second species appears at a MW
consistent with an RNA-RlmN adduct, expected MW ∼71 kDa
(mass equivalent to 215 nt). The formation of the adduct
Figure 1. SDS-PAGE analysis of RlmN C118 mutant proteins. Protein
markers are in lane 1 of all gels. (a) C118A RlmN purified by
immobilized metal ion affinity chromatography (lane 2). (b) C118G
RlmN (lane 2) and C118S RlmN (lane 3) purified by immobilized
metal ion affinity chromatography. (c) Untreated C118A RlmN-RNA
adduct purified by anion exchange (lane 2). Sample from lane 2, after
treatment with RNases A and T1 (lane 3). (d) C118S RlmN grown
under metal-deficient conditions and purified by immobilized metal
ion affinity chromatography (lane 2). In this sample, no RNA adduct
could be detected.
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species is dependent on the presence of a complete reducing
system, as when NADPH is omitted, no gel-shifted species
appears (Figure 3, lane 3). This finding is consistent with the
role of NADPH as the ultimate electron source in the FldA/Fpr
(flavodoxin and reductase) system that leads to the reductive
cleavage of SAM, resulting in the formation of the critical 5′-dA
radical that initiates the subsequent radical-based reactions.
When the adduct species was excised from the gel and
subjected to in-gel RNase A and T1 and trypsin digestion,
subsequent LC-MS/MS experiments analogous to those above
for the in vivo adduct revealed an identical 147 Da modification
on cysteine 355 of C118S mutant protein exposed to rRNA
substrate (Figure S5), again consistent with the proposed
methylene-linked adenosine intermediate (VI in Scheme 1).
These in vitro experiments with defined RNA substrate
demonstrate that a covalent adduct is formed between RlmN
cysteine 118 mutant enzyme and rRNA substrate.
To further interrogate the mechanism of formation of this
intermediate arrested in mutant enzymes, the incorporation of
deuterium into the protein-RNA adduct was examined. RlmN
C118S mutant protein was expressed in minimal media in the
presence of a strong chelator, resulting in protein lacking both
the iron−sulfur cluster and methylation at cysteine 355.53 The
Fe−S cluster of this apoprotein was then chemically
reconstituted, resulting in [4Fe-4S]-containing RlmN C118S
enzyme with a free thiol at cysteine 355. This protein was then
incubated with the same RNA fragment as above and
[methyl-2H3]-SAM. In a separate experiment, C118S RlmN
(either free thiol or S-methyl at C355) was incubated with
unlabeled SAM and D-RNA (i.e., substrate in which all
adenosine residues have been replaced with [2-2H]-adenosine;
similar deuterium substituted rRNA has previously been
demonstrated as a substrate for RlmN15). The resulting
RNA-RlmN C118S adducts (Figure 3, lanes 6 and 7) were
digested with RNases and trypsin as above. The presence and
location of deuterium in the modified cysteine 355 peptides was
assessed by LC-MS/MS and compared to the spectra of the
same species formed from completely unlabeled reactants. In
agreement with the proposed formation of the covalent adduct
via addition of the thiomethylene radical into the substrate
adenine (Scheme 1), the species generated from [methyl-2H3]-
SAM and unlabeled RNA incorporates two deuterium atoms
into the group modifying cysteine 355, consistent with a CD2-
methylene linkage between the cysteine 355 sulfur and the
adenine ring (Figure 4). Reactions with unlabeled SAM and D-
RNA yielded MS and MS/MS data (Figure S6) indistinguish-
able from those generated by reactions with completely
Figure 2. Ion trap CID data of 348GDDIDAAC(CH2adenine)GQLAGDVIDR
375 formed from RlmN C118A protein in vivo and subsequently RNase
treated. The precursor mass was m/z(3+) = 650.9631, within ∼1 ppm of the calculated mass of 650.9623 (3+ ion of RlmN 348−375 peptide
+CH2adenine). The table at right lists all main sequence ions detected within 20 ppm of the calculated value. In comparison to the methyl derivative
(Figure S3), the higher charge state of the precursor ion yielding the best CID data as well as the presence of doubly charged N- and C-terminal
fragments clearly indicate the incorporation of a basic modification. The site of modification within the peptide and the deduced structure of the
modification are highlighted in yellow.
Figure 3. In vitro gel-shift assay of RlmN C118 mutants. RlmN mutant
proteins were incubated with RNA fragments as indicated, and RNA
was separated by denaturing PAGE and visualized with ethidium
bromide. Lane 1, RNA markers of the indicated size, in nt; lane 2, only
the 87 nt RNA fragment used in assays; lane 3, a negative control
lacking NADPH; lane 4, reaction with C118A RlmN, SAM, and RNA;
lane 5, reaction with C118S RlmN, SAM, and RNA; lane 6, reaction
with C118S RlmN, SAM, and D-RNA; lane 7, reaction with C118S
RlmN, [methyl-2H3]-SAM, and RNA.
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unlabeled precursors (Figure S5), consistent with the loss of
the amidine proton from the RNA-protein adduct to an
adjacent, solvent shielded, general base. This result agrees with
the previously observed retention of deuterium label in product
2-methyladenosine,15 as the shielded proton is returned to
product only subsequent to resolution of the adduct. Such
retention in the product of a proton abstracted from substrate
has previously been observed.61,62
■ DISCUSSION
The radical SAM methyl synthases, RlmN and Cfr, utilize a
novel, methyl group assembly mechanism to achieve
methylation of the 2- and 8-amidine carbons of A2503 within
23S rRNA, thereby exerting significant influence on the
biological function of the modified ribosomes.8,13 Multiple
mechanistic scenarios have been suggested to account for the
experimental findings.14,15 In this work, we provide strong
evidence for the mechanism invoking methylation of a cysteine
residue in the protein and subsequent formation of a covalent
RNA-protein adduct as originally proposed by Grove et al.14
Importantly, our mutagenesis-enabled trapping of the covalent
intermediate provides the first direct evidence of any of the
proposed reactive intermediates occurring subsequent to the
initial electron insertion.
Crucial to this mechanism are cysteine residues 118 and 355
in E. coli RlmN, which are conserved among RlmN and Cfr
homologues across species.49 We have investigated the roles of
both cysteines in this study. For cysteine 355, we examined
methylation status under endogenous conditions. We showed
that protein produced from the genomic copy of rlmN under
the native promoter at the time of maximal protein expression
and ribosome biosynthesis exhibits methylation at C355. The
fact that this modification is observed during optimal growth
strongly implies that this modification is involved in the in vivo
rRNA methylation catalyzed by RlmN, confirming its catalytic
relevance. Interestingly, methylation of a reactive cysteine in the
active site of the DNA methyltransferase Dnmt3a has recently
been observed and attributed to either spurious methylation of
a nucleophilic cysteine residue or a regulatory mechanism
inactivating excess enzyme in the absence of substrate.63 While
either of these possibilities are conceivable for RlmN, the above
argument suggests that, for RlmN, this methylation is directly
involved in catalysis.
For cysteine 118, the resolving cysteine, we examined C118A
and C118S mutant RlmN to obtain insight into the covalent
RlmN-RNA species formed both in vivo and in vitro. Previous
studies showed that purified C118A RlmN exhibited an
absorbance maximum at 265 nm vs 278 nm for WT,14 and
that ribonuclease and phosphatase treatment of these samples
released nucleotides including pseudouridine.14 Our observa-
tion of the significant increase in anionic character of this
species, as revealed by ion exchange chromatography, as well as
the gel shift upon ribonuclease treatment together strongly
argue that this species is a covalent adduct between RNA and
RlmN. Significantly, LC-MS/MS experiments localize the site
of RNA modification to cysteine 355 on RlmN. This cysteine
exhibits a +147 modification consistent with a methylene-linked
adenosine covalent intermediate in the RlmN mechanism.
The in vivo formation of a protein-RNA adduct with cysteine
118 mutant enzymes can be recapitulated in vitro, with the
formation dependent on the putative in vivo reducing system,
FldA and ferrodoxin:NADPH oxidoreductase. Further, the
incorporation of two deuterium atoms into the in vitro adduct
from [methyl-2H3]-SAM, as determined by LC-MS/MS,
supports the addition of the cysteine 355-derived thio-
methylene radical into the substrate adenosine in RNA. The
lack of deuterium in the intermediate formed from D-RNA is
consistent with the one electron oxidation of the initial adduct
(IV in scheme 1) and subsequent deprotonation, leading to re-
aromatization of adenine and the formation of the methylene-
linked RNA-cysteine 355 adduct. The observed incorporation
of deuterium from labeled substrates into the covalent adduct is
Figure 4. Ion trap CID data of 348GDDIDAAC(CD2adenine)GQLAGDVIDR
375 formed from RlmN C118S protein in vitro in the presence of
[methyl-2H3]-SAM. The precursor mass was m/z(3+) = 651.6353, within 3 ppm of the calculated mass of 651.6332 (3+ ion of RlmN 348−375
peptide +CD2adenine). Fragments that showed the 2 Da shift due to deuterium incorporation are labeled with asterisks. Main sequence ions
detected are shown in red in the table. The site of modification within the peptide and the deduced structure of the modification are highlighted in
yellow.
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indicated in Scheme 2. Our results demonstrate the obligatory
role of cysteine 118 in product formation, specifically by acting
subsequent to the formation of the covalent intermediate.
These observed critical roles for both cysteines 118 and 355
agree well with the prior in vivo observations that Cfr C105A
and C338A mutants are not resistant to florfenicol or tiamulin,
and short polynucleotides, encompassing A2503, isolated from
the rRNA of these mutant strains exhibit no methylation by
MALDI-MS analysis.49
We also note that the adduct formed by cysteine 118
mutants both in vivo and in vitro remains relatively stable in the
presence of high concentrations of thiol reducing agents. The in
vivo adducts were purified in the presence of 10 mM β-
mercaptoethanol or 5 mM DTT depending on the purification
step. Despite this exposure, the covalent RNA adduct is not
resolved during purification. The in vitro adducts were formed
in the presence of 1 mM DTT, indicating that low
concentrations of this reagent do not perturb this intermediate.
Further, when the in vivo adduct is prepared for SDS-PAGE, it
is exposed to ∼350 mM β-mercaptoethanol under denaturing
conditions, yet the RNA-modified band is still evident.
Cumulatively, these observations indicate that a sulfur
nucleophile is necessary, though not sufficient, to resolve the
covalent RNA-protein adduct. This may be due to conforma-
tional constraints on the approach of the nucleophile, possibly
concomitant with protonation of the intermediate, which is
unlikely to be readily accomplished with externally supplied
thiol.
■ CONCLUSION
In summary, the findings presented here clearly support the
existence and the intermediacy of the covalent adduct between
RlmN and rRNA substrates and highlight the crucial roles for
the two conserved cysteines unassociated with the [4Fe-4S]
cluster. These results lend experimental evidence to the
proposed mechanism14 that combines two canonical roles of
the common metabolite S-adenosylmethionine: methylation
and radical activation. The unique methylations catalyzed by
RlmN and Cfr at aromatic amidine positions of a critically
positioned nucleotide enable the modification of complex RNA
substrates with significant biological impact.
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(40) Hernańdez, H. L.; Pierrel, F.; Elleingand, E.; García-Serres, R.;
Huynh, B. H.; Johnson, M. K.; Fontecave, M.; Atta, M. Biochemistry
2007, 46, 5140.
(41) Layer, G.; Moser, J.; Heinz, D. W.; Jahn, D.; Schubert, W.-D.
EMBO J. 2003, 22, 6214.
(42) Layer, G.; Kervio, E.; Morlock, G.; Heinz, D. W.; Jahn, D.;
Retey, J.; Schubert, W. D. Biol. Chem. 2005, 386, 971.
(43) Layer, G.; Pierik, A. J.; Trost, M.; Rigby, S. E.; Leech, H. K.;
Grage, K.; Breckau, D.; Astner, I.; Jan̈sch, L.; Heathcote, P.; Warren,
M. J.; Heinz, D. W.; Jahn, D. J. Biol. Chem. 2006, 281, 15727.
(44) Fang, Q.; Peng, J.; Dierks, T. J. Biol. Chem. 2004, 279, 14570.
(45) Grove, T. L.; Lee, K. H.; St Clair, J.; Krebs, C.; Booker, S. J.
Biochemistry 2008, 47, 7523.
(46) Zhang, Y.; Zhu, X.; Torelli, A. T.; Lee, M.; Dzikovski, B.;
Koralewski, R. M.; Wang, E.; Freed, J.; Krebs, C.; Ealick, S. E.; Lin, H.
Nature 2010, 465, 891.
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